ClinicalTrials.gg
CompletedNCT02874742Updated Feb 4, 2025Results posted

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

A Phase 2 interventional study of Lenalidomide and Bortezomib in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
39th of 249
224 · median 50
Started
2016
with 11 others
Phase 2
124 of 249
12 open now
Registered
153rd of 249
by date

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 39th largest by enrollment, is one of 12 that started in 2016, is one of 124 in phase 2, and was the 153rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Considered by the investigator to be eligible for high-dose chemotherapy (HDT) and stem cell transplantation (ASCT) according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory studies
  • Has not had prior systemic therapy for multiple myeloma. An emergency course of (defined as no greater than 40 milligram [mg] of dexamethasone, or equivalent per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. In addition, radiation therapy is permitted prior to study entry, during screening, and during Cycles 1-2 of study treatment as needed for lytic bone disease
  • (ECOG) performance status score of 0, 1, or 2
  • Woman of must have 2 negative highly sensitive serum (beta-human chorionic gonadotropin [b-hCG]) during screening, the first one within 10 to 14 days prior to the first dose of any component of study treatment and the second within 24 hours prior to the first dose of any component of study treatment
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study (including during dose interruptions), and for 4 weeks following discontinuation of lenalidomide, and if receiving daratumumab, for 3 months after the last dose

Exclusion criteria

Exclusion Criteria:

  • Diagnosed or treated for other than multiple myeloma, except: a) Malignancy treated with curative intent and with no known active disease present for more than equal to (>= )3 years before randomization; b) Adequately treated non-melanoma skin cancer, lentigo maligna or in situ malignancies (including but not limited to, cervical, breast) with no evidence of disease
  • Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma
  • Known with a (FEV1) less than (\<)50 percent (%) of predicted normal
  • Known moderate or severe persistent asthma within the past 2 years or currently has uncontrolled asthma of any classification
  • Known to be seropositive for , known to have surface antigen positivity, or known to have a history of . Participants who completed treatment for hepatitis C at least 6 months prior to screening and have no detectable circulating hepatitis C virus (HCV) at screening, may participate in the study. Such participants will be required to undergo regular assessment for HCV reactivation during their participation in the study. Participants who test positive for HCV at any time during these assessments will be withdrawn from the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)

    Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.

    Drug: Lenalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Lenalidomide+Bortezomib+Dexamethasone (RVd)

    Participants will receive lenalidomide, bortezomib and dexamethasone.

    Drug: Lenalidomide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.

  • Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.

  • Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).

  • Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Stringent Complete Response (sCR)

    Percentage of participants who had achieved sCR as determined by the validated computer algorithm according to the International Myeloma Working Group (IMWG) criteria, by the end of post-autologous stem cell transplantation (post-ASCT) consolidation treatment were reported. Complete response (CR) is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

    Time frame: From randomization to post-ASCT consolidation (after Cycle 6) before maintenance treatment (up to 10 months)

Secondary outcomes

  1. Percentage of Participants With Complete Response (CR) or Better

    CR or better rate is defined as the percentage of participants who achieve CR or sCR, according to the IMWG criteria. CR is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. For 2 participants (1 in each randomized treatment group), data were updated by the study sites which resulted in their inclusion to the response-evaluable analysis set after the primary analysis.

    Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)

  2. Percentage of Participants With Overall Stringent Complete Response (sCR)

    Overall sCR rate is defined as the percentage of participants who achieved sCR, according to the IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5 % PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

    Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)

  3. Percentage of Participants With Overall Response Rate (ORR)

    ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response \[VGPR\], CR or sCR) based on computerized algorithm as per IMWG criteria. PR -greater than or equal to (\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required. A \>=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

    Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)

  4. Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better

    VGPR or better rate is defined as the percentage of participants who achieved VGPR or better, according to the IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours.

    Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)

  5. Percentage of Participants With Negative Minimal Residual Disease (MRD)

    Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. Minimal residual disease was evaluated in participants who achieved CR or sCR (including participants with VGPR or better and suspected daratumumab interference) using next-generation sequencing which utilizes multiple myeloma cell DNA from bone marrow aspirates at a threshold of less than (\<) 10\^5.

    Time frame: From randomization to end of following: induction treatment, post-ASCT consolidation (after Cycle 6) (up to 4.5 months), and at the end of maintenance period of 24 months (overall duration up to 34 months)

  6. Duration of Complete Response or Better

    Duration of CR or better is the duration from the date of initial documentation of a CR or sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease (PR), or relapse from CR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligrams \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cells (PCs) proliferative disorder.

    Time frame: From randomization to the date of first documented evidence of progressive disease or relapse from CR (up to 5 years)

  7. Duration of Stringent Complete Response (sCR)

    Duration of sCR is the duration from the date of initial documentation of a sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease, or relapse from sCR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From randomization to the date of first documented evidence of progressive disease or relapse from sCR (up to 5 years)

  8. Time to Stringent Complete Response (sCR)

    Time to sCR is the duration from the date of randomization to the date of initial documentation of sCR, which was confirmed by a repeated measurement as required by the IMWG criteria.

    Time frame: From randomization to the date of initial documentation of sCR (up to 5 years)

  9. Time to Complete Response or Better

    Time to CR or better is the duration from the date of randomization to the date of initial documentation of CR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

    Time frame: From randomization to the date of initial documentation of CR (up to 5 years)

  10. Time to Very Good Partial Response (VGPR) or Better

    Time to VGPR or better is the duration from the date of randomization to the date of initial documentation of VGPR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

    Time frame: From randomization to the date of initial documentation of VGPR or better (up to 5 years)

  11. Time to Partial Response (PR) or Better

    Time to PR or better is the duration from the date of randomization to the date of initial documentation of PR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

    Time frame: From randomization to the date of initial documentation of PR or better (up to 5 years)

  12. Progression-free Survival (PFS)

    PFS is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease or death, whichever comes first. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From randomization to the date of first documented evidence of progressive disease or death (up to 5 years)

  13. Overall Survival (OS)

    OS is measured from the date of randomization to the date of the participant's death.

    Time frame: From randomization to the date of initial documentation of participant's death (up to 5 years)

  14. Time to Progression (TTP)

    TTP is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease according to the IMWG criteria.

    Time frame: From randomization to the date of first documented evidence of progressive disease (up to 5 years)

  15. Duration of Response

    Duration of response is defined as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive (up to 5 years)

07

Results

Posted Feb 7, 2020
Limitations and caveats
Initial protocol did not require minimal residual disease (MRD) testing in all participants, impacting the interpretation of MRD negativity rates in intent-to-treat (ITT) group, which strongly favored daratumumab treatment. Sensitivity analysis, including MRD negativity rate in participants with a complete response (CR) or better and with an informative baseline clone and follow-up MRD testing, were performed and confirmed a strong benefit for daratumumab treatment.

Participant flow

223 participants were enrolled/randomized (16 in safety run-in,104 to D-RVd and 103 to RVd group). Among 207 (D-RVd \[104\]+RVd \[103\]) randomized, 201 received treatment (D-RVd: 100 and RVd: 101). 1 participant randomized to D-RVd group received RVd treatment and was randomized twice (resulting a total of 224 participants).

Participant flow — Overall Study
MilestoneRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Started10310416
Treated (safety analysis set)10110016
Completed768815
Not completed27161
Withdrew: Death010
Withdrew: Lost to follow-up541
Withdrew: Withdrawal by subject1780
Withdrew: Other410
Withdrew: Progressive disease100
Withdrew: Screen failure020

Outcome measures

PrimaryPercentage of Participants With Stringent Complete Response (sCR)

Percentage of participants who had achieved sCR as determined by the validated computer algorithm according to the International Myeloma Working Group (IMWG) criteria, by the end of post-autologous stem cell transplantation (post-ASCT) consolidation treatment were reported. Complete response (CR) is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

Time frame:
From randomization to post-ASCT consolidation (after Cycle 6) before maintenance treatment (up to 10 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Stringent Complete Response (sCR)
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)
Percentage of Participants With Stringent Complete Response (sCR)32.0 (22.9 to 42.2)42.4 (32.5 to 52.8)
SecondaryPercentage of Participants With Complete Response (CR) or Better

CR or better rate is defined as the percentage of participants who achieve CR or sCR, according to the IMWG criteria. CR is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. For 2 participants (1 in each randomized treatment group), data were updated by the study sites which resulted in their inclusion to the response-evaluable analysis set after the primary analysis.

Time frame:
From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (CR) or Better
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
At the end of induction prior to ASCT13.4 (7.3 to 21.8)19.2 (12.0 to 28.3)12.5 (1.6 to 38.3)
At the end of ASCT prior to consolidation19.6 (12.2 to 28.9)27.3 (18.8 to 37.1)56.3 (29.9 to 80.2)
At the end of post-ASCT consolidation42.3 (32.3 to 52.7)51.5 (41.3 to 61.7)68.8 (41.3 to 89.0)
At the end of maintenance period (up to 24 Months)60.2 (49.8 to 70.0)83.0 (74.2 to 89.8)93.8 (69.8 to 99.8)
SecondaryPercentage of Participants With Overall Stringent Complete Response (sCR)

Overall sCR rate is defined as the percentage of participants who achieved sCR, according to the IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5 % PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

Time frame:
From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Stringent Complete Response (sCR)
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
At the end of induction prior to ASCT7.2 (3.0 to 14.3)12.1 (6.4 to 20.2)0 (NA to NA)
At the end of ASCT prior to consolidation14.4 (8.1 to 23.0)21.2 (13.6 to 30.6)43.8 (19.8 to 70.1)
At the end of post-ASCT consolidation32.0 (22.9 to 42.2)42.4 (32.5 to 52.8)56.3 (29.9 to 80.2)
At the end of Maintenance Treatment (up to 24 Months)48.0 (37.8 to 58.3)67.0 (56.9 to 76.1)93.8 (69.8 to 99.8)
SecondaryPercentage of Participants With Overall Response Rate (ORR)

ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response \[VGPR\], CR or sCR) based on computerized algorithm as per IMWG criteria. PR -greater than or equal to (\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required. A \>=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.

Time frame:
From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response Rate (ORR)
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
At the end of induction prior to ASCT91.8 (84.4 to 96.4)98.0 (92.9 to 99.8)100 (79.4 to 100)
At the end of ASCT prior to consolidation91.8 (84.4 to 96.4)99.0 (94.5 to 100)100 (79.4 to 100)
At the end of post-ASCT consolidation91.8 (84.4 to 96.4)99.0 (94.5 to 100)100 (79.4 to 100)
At the End of Maintenance Treatment (up to 24 Months)91.8 (84.5 to 96.4)99.0 (94.6 to 100.0)100.0 (79.4 to 100.0)
SecondaryPercentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better

VGPR or better rate is defined as the percentage of participants who achieved VGPR or better, according to the IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours.

Time frame:
From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
At the end of induction prior to ASCT56.7 (46.3 to 66.7)71.7 (61.8 to 80.3)68.8 (41.3 to 89.0)
At the end of ASCT prior to consolidation66.0 (55.7 to 75.3)86.9 (78.6 to 92.8)100 (79.4 to 100)
At the end of post-ASCT consolidation73.2 (63.2 to 81.7)90.9 (83.4 to 95.8)100 (79.4 to 100)
At the End of Maintenance Period (up to 24 Months)77.6 (68.0 to 85.4)96.0 (90.1 to 98.9)100.0 (79.4 to 100.0)
SecondaryPercentage of Participants With Negative Minimal Residual Disease (MRD)

Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. Minimal residual disease was evaluated in participants who achieved CR or sCR (including participants with VGPR or better and suspected daratumumab interference) using next-generation sequencing which utilizes multiple myeloma cell DNA from bone marrow aspirates at a threshold of less than (\<) 10\^5.

Time frame:
From randomization to end of following: induction treatment, post-ASCT consolidation (after Cycle 6) (up to 4.5 months), and at the end of maintenance period of 24 months (overall duration up to 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Percentage of participantsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
MRD from randomization to prior to ASCT (10^5)7.8 (3.4 to 14.7)22.1 (14.6 to 31.3)18.8 (4.0 to 45.6)
Post ASCT consolidation (10^5)20.4 (13.1 to 29.5)50.0 (40.0 to 60.0)50.0 (24.7 to 75.3)
At the End of Maintenance Period (up to 24 Months) (10^5)30.1 (21.5 to 39.9)64.4 (54.4 to 73.6)81.3 (54.4 to 96.0)
SecondaryDuration of Complete Response or Better

Duration of CR or better is the duration from the date of initial documentation of a CR or sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease (PR), or relapse from CR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligrams \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cells (PCs) proliferative disorder.

Time frame:
From randomization to the date of first documented evidence of progressive disease or relapse from CR (up to 5 years)
Reported as:
Median · Months
Duration of Complete Response or Better
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Duration of Complete Response or BetterNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryDuration of Stringent Complete Response (sCR)

Duration of sCR is the duration from the date of initial documentation of a sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease, or relapse from sCR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From randomization to the date of first documented evidence of progressive disease or relapse from sCR (up to 5 years)
Reported as:
Median · Months
Duration of Stringent Complete Response (sCR)
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Duration of Stringent Complete Response (sCR)NA (NA to NA)NA (NA to NA)NA (42.4 to NA)
SecondaryTime to Stringent Complete Response (sCR)

Time to sCR is the duration from the date of randomization to the date of initial documentation of sCR, which was confirmed by a repeated measurement as required by the IMWG criteria.

Time frame:
From randomization to the date of initial documentation of sCR (up to 5 years)
Reported as:
Median · Months
Time to Stringent Complete Response (sCR)
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Time to Stringent Complete Response (sCR)14.3 (9.2 to 21.7)10.2 (8.8 to 13.0)8.4 (7.1 to 15.2)
SecondaryTime to Complete Response or Better

Time to CR or better is the duration from the date of randomization to the date of initial documentation of CR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

Time frame:
From randomization to the date of initial documentation of CR (up to 5 years)
Reported as:
Median · Months
Time to Complete Response or Better
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Time to Complete Response or Better9.6 (8.4 to 12.2)8.9 (7.9 to 9.4)7.7 (6.7 to 9.7)
SecondaryTime to Very Good Partial Response (VGPR) or Better

Time to VGPR or better is the duration from the date of randomization to the date of initial documentation of VGPR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

Time frame:
From randomization to the date of initial documentation of VGPR or better (up to 5 years)
Reported as:
Median · Months
Time to Very Good Partial Response (VGPR) or Better
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Time to Very Good Partial Response (VGPR) or Better3.0 (2.2 to 6.3)2.2 (2.1 to 2.7)2.1 (0.9 to 6.7)
SecondaryTime to Partial Response (PR) or Better

Time to PR or better is the duration from the date of randomization to the date of initial documentation of PR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.

Time frame:
From randomization to the date of initial documentation of PR or better (up to 5 years)
Reported as:
Median · Months
Time to Partial Response (PR) or Better
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Time to Partial Response (PR) or Better0.8 (0.8 to 1.0)0.8 (0.8 to 0.8)0.8 (0.7 to 1.4)
SecondaryProgression-free Survival (PFS)

PFS is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease or death, whichever comes first. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From randomization to the date of first documented evidence of progressive disease or death (up to 5 years)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)NA (57.6 to NA)
SecondaryOverall Survival (OS)

OS is measured from the date of randomization to the date of the participant's death.

Time frame:
From randomization to the date of initial documentation of participant's death (up to 5 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Progression (TTP)

TTP is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease according to the IMWG criteria.

Time frame:
From randomization to the date of first documented evidence of progressive disease (up to 5 years)
Reported as:
Median · Months
Time to Progression (TTP)
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Time to Progression (TTP)NA (NA to NA)NA (NA to NA)NA (57.59 to NA)
SecondaryDuration of Response

Duration of response is defined as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive (up to 5 years)
Reported as:
Median · Months
Duration of Response
MonthsRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
Duration of ResponseNA (NA to NA)NA (NA to NA)NA (56.8 to NA)

Adverse events

Collected over Other adverse events and serious adverse events: up to 30 days after the last dose of study treatment (up to 3 years); All-cause mortality: up to end of study (up to 5 years). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)7/103 (6.8%)53/102 (52%)102/102 (100%)
Randomized: Daratumumab+RVd (D-RVd)7/104 (6.7%)46/99 (46.5%)99/99 (100%)
Safety Run-in: D-RVd1/16 (6.3%)12/16 (75%)16/16 (100%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
PneumoniaInfections and infestations14/10215/995/16
Febrile NeutropeniaBlood and lymphatic system disorders1/1023/993/16
PyrexiaGeneral disorders10/10211/991/16
Atrial TachycardiaCardiac disorders1/1020/991/16
Abdominal Pain UpperGastrointestinal disorders0/1020/991/16
NauseaGastrointestinal disorders0/1023/991/16
OesophagitisGastrointestinal disorders0/1020/991/16
VomitingGastrointestinal disorders0/1022/991/16
Cholecystitis AcuteHepatobiliary disorders0/1020/991/16
Escherichia InfectionInfections and infestations0/1020/991/16
Most frequent other events
Showing 10 of 302
Most frequent other events
EventRandomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVd
LymphopeniaBlood and lymphatic system disorders29/10231/9913/16
NeutropeniaBlood and lymphatic system disorders41/10263/9913/16
CoughRespiratory, thoracic and mediastinal disorders30/10253/9912/16
FatigueGeneral disorders63/10271/9910/16
Upper Respiratory Tract InfectionInfections and infestations51/10267/9911/16
DiarrhoeaGastrointestinal disorders56/10265/9910/16
LeukopeniaBlood and lymphatic system disorders30/10239/9910/16
ConstipationGastrointestinal disorders42/10251/996/16
NauseaGastrointestinal disorders51/10251/996/16
ThrombocytopeniaBlood and lymphatic system disorders36/10244/998/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVdTotal
Mean59 ± 7.2757.2 ± 9.7959.8 ± 5.9658.2 ± 8.49
Sex: Female, Male
Sex: Female, Male(Participants)Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVdTotal
Female4346897
Male60588126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVdTotal
American Indian or Alaska Native0000
Asian2013
Black or African American1814436
Native Hawaiian or Other Pacific Islander0000
White768511172
More than one race1001
Unknown or Not Reported5308
Other1203
Region of Enrollment
Region of Enrollment(Participants)Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd)Randomized: Daratumumab+RVd (D-RVd)Safety Run-in: D-RVdTotal
UNITED STATES10310416223
08

Study locations

36 sites
  • Birmingham, Alabama, United States
  • Duarte, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Westwood, Kansas, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Detroit, Michigan, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Abington, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD Jr, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022 Nov;199(3):355-365. doi: 10.1111/bjh.18432. Epub 2022 Sep 16. PubMed 36111391 ↗
  • Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. PubMed 35985959 ↗
  • Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y, Bobba P, Hoehn D, Pei H, Ukropec J, Qi M, Lin TS, Richardson PG. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021 Feb 23;5(4):1092-1096. doi: 10.1182/bloodadvances.2020003642. PubMed 33606004 ↗
  • Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288. PubMed 32325490 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2019, 28 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 28 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2016
First posted
Aug 22, 2016
StartActual
Aug 29, 2016
Primary completionActual
Jan 25, 2019
CompletionActual
Apr 8, 2022
Results first posted
Feb 7, 2020
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02874742
Responsible party
Sponsor
First posted
Aug 22, 2016
Start date
Aug 29, 2016
Primary completion
Jan 25, 2019
Completion
Apr 8, 2022
Results posted
Feb 7, 2020
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Bortezomib · Dexamethasone

Start the discussion